IRIS
VETTORI, Serena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.458
NA - Nord America 1.981
AS - Asia 1.846
SA - Sud America 416
AF - Africa 30
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 1
Totale 8.737
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 2.741
US - Stati Uniti d'America 1.913
SG - Singapore 708
IE - Irlanda 492
CN - Cina 375
BR - Brasile 356
HK - Hong Kong 299
UA - Ucraina 214
GB - Regno Unito 207
DE - Germania 203
VN - Vietnam 202
FR - Francia 180
IT - Italia 172
TR - Turchia 77
GR - Grecia 67
FI - Finlandia 62
KR - Corea 57
SE - Svezia 50
CA - Canada 42
IN - India 36
BE - Belgio 30
AR - Argentina 28
EC - Ecuador 11
IQ - Iraq 11
MX - Messico 11
BD - Bangladesh 10
ID - Indonesia 10
JP - Giappone 10
AT - Austria 9
ZA - Sudafrica 9
PK - Pakistan 8
CO - Colombia 7
NL - Olanda 7
UZ - Uzbekistan 7
KE - Kenya 6
PE - Perù 6
EG - Egitto 5
CH - Svizzera 4
EU - Europa 4
HR - Croazia 4
PH - Filippine 4
TH - Thailandia 4
TN - Tunisia 4
VE - Venezuela 4
AZ - Azerbaigian 3
ES - Italia 3
HU - Ungheria 3
KZ - Kazakistan 3
NI - Nicaragua 3
PL - Polonia 3
SA - Arabia Saudita 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BW - Botswana 2
BY - Bielorussia 2
CL - Cile 2
CU - Cuba 2
CZ - Repubblica Ceca 2
GT - Guatemala 2
IL - Israele 2
IR - Iran 2
JO - Giordania 2
MA - Marocco 2
NP - Nepal 2
BB - Barbados 1
BN - Brunei Darussalam 1
DZ - Algeria 1
GE - Georgia 1
HN - Honduras 1
JM - Giamaica 1
KG - Kirghizistan 1
KI - Kiribati 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
MN - Mongolia 1
MY - Malesia 1
OM - Oman 1
PA - Panama 1
PY - Paraguay 1
SN - Senegal 1
SV - El Salvador 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.737
Salva come PNG Salva come JPEG
Città #
Moscow 982
Dublin 491
Jacksonville 361
Santa Clara 329
Hong Kong 292
Singapore 289
San Jose 142
Chandler 124
Beijing 93
Bremen 77
Ashburn 75
Princeton 75
Ho Chi Minh City 74
Ann Arbor 73
Medford 60
Seoul 57
Roxbury 55
Hanoi 42
Wilmington 38
Woodbridge 35
Hefei 33
Brussels 30
Caserta 28
Des Moines 28
Ottawa 25
Boardman 23
Cambridge 21
Bengaluru 20
Munich 20
San Mateo 20
São Paulo 19
Haiphong 18
Dallas 16
Frankfurt am Main 15
Mountain View 15
New York 14
Rio de Janeiro 14
Los Angeles 13
Napoli 13
The Dalles 12
Brasília 10
Guangzhou 10
Helsinki 10
Biên Hòa 9
Curitiba 9
Da Nang 9
Falls Church 9
Düsseldorf 8
Jinan 8
Nanjing 8
Nuremberg 8
Auburn Hills 7
Belo Horizonte 7
Fiano Romano 7
Orem 7
Changsha 6
Chicago 6
Dong Ket 6
Falkenstein 6
Fortaleza 6
Guayaquil 6
Hanover 6
Johannesburg 6
Nairobi 6
Tashkent 6
Tokyo 6
Baghdad 5
Dhaka 5
London 5
Maceió 5
Montréal 5
Naples 5
Brooklyn 4
Cairo 4
Hebei 4
João Pessoa 4
Lagoa Santa 4
Lima 4
Milan 4
Ningbo 4
Norwalk 4
Piracicaba 4
Porto Alegre 4
Recife 4
Roubaix 4
San Francisco 4
Seattle 4
São Bernardo do Campo 4
Toronto 4
Turin 4
Amsterdam 3
Ankara 3
Baku 3
Bauru 3
Blumenau 3
Bogotá 3
Cabo Frio 3
Council Bluffs 3
Erbil 3
Houston 3
Totale 4.485
Salva come PNG Salva come JPEG
Nome #
Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. 199
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 183
CLINICAL AND SUBCLINICAL ATHEROSCLEROSIS IN SYSTEMIC SCLEROSIS (SSC) PATIENTS 177
Clinical correlates of human leukocyte antigen-G (HLA-G) in systemic sclerosis. 165
Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease. 155
CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc) 155
Early systemic sclerosis: Analysis of the disease course in patients with marker autoantibody or capillaroscopic positivity or both. 154
Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey 152
ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. 146
Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. 145
[Survival and death causes in 251 systemic sclerosis patients from a single Italian center]. 144
[Hypocomplementemia in systemic sclerosis]. 139
Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency 138
Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression 136
CROSS-SECTIONAL EVALUATION OF CHEMOKINE PROFILE IN EARLY AND DEFINITE SYSTEMIC SCLEROSIS 134
Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis 134
Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features 130
CARDIAC BLOCKS IN SYSTEMIC SCLEROSIS: PREVALENCE AND ASSOCIATED FEATURES IN THE EUSTAR COHORT 129
Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database 129
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 129
Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis 126
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study 124
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index 124
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research 123
Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. 123
European Scleroderma Study Group (ESCSG) Activity Index is correlated to quality of life measures both at admission and overtime 120
Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. 119
High IL-17E and Low IL-17C Dermal Expression Identifies a Fibrosis-Specific Motif Common to Morphea and Systemic Sclerosis. 118
Tissue Doppler imaging in systemic sclerosis: A 3-year longitudinal study. 118
Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review 117
Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels. 117
Mapping and predicting mortality from systemic sclerosis 115
Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy 112
T-Cell Proapoptotic and Antifibrotic Activity Against Autologous Skin Fibroblasts in vitro Is Associated With IL-17A Axis Upregulation in Systemic Sclerosis 109
Right atrial morphology and function in patients with systemic sclerosis compared to healthy controls: a two-dimensional strain study 108
Peripheral blood mononuclear cells (PBMCs) of systemic sclerosis patients induce apoptosis in cocultured autologous fibroblasts and up-regulate HLA-DR and FASL 108
Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: A EUSTAR analysis 107
Fulminant Myocarditis Unmasking Adult-Onset Still's Disease and Desmoplakin Truncation 106
Functional changes in scleroderma fibroblasts co-cultured with autologous peripheral blood mononuclear cells (PBMCS) 106
Early systemic sclerosis: short –term disease evolution and factors predidting the development of new manifestations of organ involvement 106
SAT0181 CXCL4 Is Not A Biomarker in Rheumatoid Arthritis Patients Treated with Abatacept and Tocilizumab 106
The Concept of Early Systemic Sclerosis Following 2013 ACR\EULAR Criteria for the Classification of Systemic Sclerosis. 104
Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role? 102
SURNATANTS FROM SYSTEMIC SCLEROSIS PBMCS CO-CULTURED WITH AUTOLOGOUS FIBROBLASTS DISPLAY HIGH LEVELS OF PRO-FIBROTIC CYTOKINES 101
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management 101
Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database 100
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study 99
Serum CXCL4 Increase in Patients with Undifferentiated Connective Tissue Disease at Risk for Systemic Sclerosis Is Associated with Anti-Scl70 Antibodies and ICAM-1, a Marker of Endothelial Activation 98
Serum CXCL4 increase in primary Sjögren’s syndrome characterizes patients with microvascular involvement and reduced salivary gland infiltration and lymph node involvement 98
Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group 97
The cumulative number of micro-haemorrhages and micro-thromboses in nailfold videocapillaroscopy is a good indicator of disease activity in systemic sclerosis: A validation study of the NEMO score 97
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease 96
FRI0446 Severe Heart Disease in Systemic Sclerosis: Prevalence, Risk Factors and Current Treatment. A Eustar-Desscipher Study 96
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database 95
The β-fibrinogen -455 G>A gene polymorphism is associated with peripheral vascular injury in systemic sclerosis patients 95
Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study 95
Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: A longitudinal EUSTAR study 94
Role of microRNAs in fibrosis 93
Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis 93
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 93
Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis 92
Longitudinal analysis of quality of life in patients with undifferentiated connective tissue diseases 91
N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis 90
Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database 89
Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database 88
FRI0522 Peripheral Blood Mononuclear Cells Co-Cultured with Autologous Skin Fibroblasts Up-Regulate IL-17A and Play Anti-Fibrotic Effects in Systemic Sclerosis 88
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease 88
Peripheral Blood Mononuclear Cells Co-Cultured With Autologous Skin Fibroblasts Up-Regulate IL-17A and Play Anti-Fibrotic Effects In Systemic Sclerosis. 86
Phenotypes determined by cluster analysis and their survival in the prospective EUSTAR cohort of patients with systemic sclerosis 86
Identification of a New Set of Activity Criteria for Systemic Sclerosis. Preliminary Report 85
Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis 85
IL-22 capacitates dermal fibroblast responses to TNF in scleroderma 83
Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension 82
Hypocomplementemia in Systemic sclerosis - Author reply 81
Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database 81
Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value 80
Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort 79
MiRs in RA: possible biomarkers and therapeutic targets 78
Progression, Management, and Outcome of Aortic Valve Stenosis in Systemic Sclerosis: A Case Series 72
What have multicentre registries across the world taught us about the disease features of systemic sclerosis? 66
Diffuse Cutaneous Systemic Sclerosis Complicated by Serum Amyloid A Protein Cardiac Amyloidosis and Cardiogenic Shock 20
Totale 8.922
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.622
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.622
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202119 0 0 0 0 0 0 0 0 0 0 0 19
2021/2022495 28 5 11 25 175 6 14 7 14 32 39 139
2022/2023809 99 56 5 29 103 38 3 28 413 7 8 20
2023/2024326 27 15 8 23 121 11 3 9 1 23 26 59
2024/20251.209 6 8 0 15 187 199 238 79 125 230 67 55
2025/20264.438 145 145 237 283 405 2.572 227 98 145 110 56 15
Totale 8.922